Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : YEEHAW CANDIDATES -- Ignore unavailable to you. Want to Upgrade?

To: lexi2004 who wrote (19649)	10/16/2006 8:04:00 PM
From: Galirayo	Respond to of 23958

I think it'll be fine .. Most Holders or Buyers are not looking at those Earnings .. they are looking to the future, .. out say .. 6 months to a year. It's a Multi Bagger in embryo if all goes right.

To: lexi2004 who wrote (19649)	10/17/2006 9:30:28 AM
From: Galirayo	Read Replies (1) \| Respond to of 23958

Generex Biotechnology Announces Filing of Its Form 10-K Annual Report for the Fiscal Year Ended July 31, 2006 Tuesday October 17, 9:15 am ET No "Going Concern" Qualification in Auditor's Report Reflecting Company's Strong Financial Condition TORONTO--(MARKET WIRE)--Oct 17, 2006 -- Generex Biotechnology Corporation (NASDAQ:GNBT - News), the leader in drug delivery for metabolic diseases through the inner lining of the mouth, announced today that it has filed its Form 10-K Annual Report for the fiscal year of the Company ended July 31, 2006 with the United States Securities and Exchange Commission. ADVERTISEMENT The audited financial statements included in the Annual Report disclose that the Company had cash, cash equivalents, and short-term investments in excess of $52 million as at July 31, 2006 which was the strongest financial position in the Company's history. Unlike previous reports, the auditor's report in respect of those financial statements does not include a "going concern" qualification. "We are pleased to file an Annual Report reflecting such a robust financial condition," said Anna Gluskin, the Company's President & Chief Executive Officer. "With these resources, we are very well positioned to continue the development and commercialization of Generex Oral-lyn(TM), our flagship oral insulin spray product, as well as the other products in our drug delivery platform pipeline and the immunotherapeutic vaccine R&D programs of our Antigen Express subsidiary, including breast and prostate cancer and avian influenza vaccines."